Botly Leigh C P, Burton Christie L, Rizos Zoë, Fletcher Paul J
Department of Psychology, University of Toronto, Toronto, Canada.
Psychopharmacology (Berl). 2008 Jul;199(1):55-66. doi: 10.1007/s00213-008-1093-z. Epub 2008 May 16.
Methylphenidate, which is used to treat attention deficit/hyperactivity disorder, increases extracellular dopamine by inhibiting the dopamine transporter. Methylphenidate has an abuse potential, and there are increasing reports of recreational use of methylphenidate. Little work has examined methylphenidate self-administration in rodent models.
This work characterized intravenous methylphenidate self-administration in rats, determined whether dopamine mediates its reinforcing effects and examined the influence of route of administration on the ability of methylphenidate to reinstate extinguished drug-seeking behaviour.
Rats were trained to self-administer methylphenidate (0.25 mg per infusion) via an intravenous catheter according to a fixed ratio 1 (FR1) or progressive ratio (PR) schedule. The effects of manipulating the dose of methylphenidate and of treatment with the dopamine D1 receptor antagonist SCH23390 or the dopamine D2 receptor antagonist eticlopride (both at 0.01 and 0.03 mg/kg) were examined. Finally, the ability of noncontingent administrations of methylphenidate (intraperitoneal [IP] or gavage) to reinstate extinguished drug-seeking behaviour was examined.
Rats readily self-administered methylphenidate dose dependently on FR1 and PR schedules. Treatment with SCH23390 or eticlopride increased the number methylphenidate infusions taken by rats on the FR1 schedule and reduced breaking points on the PR schedule. Following extinction of drug-seeking behaviour, methylphenidate reinstated responding and was more effective at doing so when administered IP.
These results demonstrate that intravenous methylphenidate is a reinforcer and that its reinforcing efficacy is related to increased dopamine activity at D1 and D2 receptors. Methylphenidate reinstates drug-seeking behaviour; the route of administration modifies this response suggesting that pharmacokinetic factors are important in determining methylphenidate-induced reinstatement.
用于治疗注意力缺陷多动障碍的哌甲酯,通过抑制多巴胺转运体来增加细胞外多巴胺水平。哌甲酯具有滥用可能性,且关于其被用于消遣娱乐的报道日益增多。在啮齿动物模型中,很少有研究探讨哌甲酯的自我给药情况。
本研究对大鼠静脉注射哌甲酯的自我给药行为进行了特征描述,确定多巴胺是否介导其强化作用,并考察给药途径对哌甲酯恢复已消退的觅药行为能力的影响。
训练大鼠根据固定比率1(FR1)或累进比率(PR)程序,通过静脉导管自我给药哌甲酯(每次输注0.25毫克)。考察了改变哌甲酯剂量以及用多巴胺D1受体拮抗剂SCH23390或多巴胺D2受体拮抗剂依托必利(均为0.01和0.03毫克/千克)进行治疗的效果。最后,考察了非条件性给予哌甲酯(腹腔注射[IP]或灌胃)恢复已消退的觅药行为的能力。
大鼠在FR1和PR程序上均能容易地按剂量依赖性方式自我给药哌甲酯。用SCH23390或依托必利治疗增加了大鼠在FR1程序上的哌甲酯输注次数,并降低了PR程序上的断点。在觅药行为消退后,哌甲酯能恢复反应,且腹腔注射给药时恢复效果更佳。
这些结果表明,静脉注射哌甲酯是一种强化剂,其强化效力与D1和D2受体处多巴胺活性增加有关。哌甲酯能恢复觅药行为;给药途径会改变这种反应,这表明药代动力学因素在决定哌甲酯诱导的恢复过程中很重要。